Showing results (1-10 of 442) with videos related to
Sort By:
Pageof 45
Expert Opinion on Biological Therapy|June 14, 2008
Adalimumab for the treatment of Crohn's diseaseShane M Devlin, Remo PanaccioneThe Medical Clinics of North America|December 1, 2009
Evolving inflammatory bowel disease treatment paradigms: top-down versus step-upShane M Devlin, Remo PanaccioneGastroenterology Clinics of North America|November 17, 2009
Evolving inflammatory bowel disease treatment paradigms: top-down versus step-upShane M Devlin, Remo PanaccioneCurrent Gastroenterology Reports|November 12, 2009
Managing the risks of IBD therapyCynthia H Seow, Shanika de Silva, Gilaad G Kaplan, et al.Crohn'S & Colitis 360|February 13, 2023
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference BiologicsRemo PanaccioneJournal of the Canadian Association of Gastroenterology|February 24, 2025
What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease?Remo PanaccioneTherapeutic Advances in Gastroenterology|December 25, 2010
Anti-adhesion molecule therapy for inflammatory bowel diseaseSubrata Ghosh, Remo PanaccioneGastroenterology Clinics of North America|August 12, 2014
Update on ustekinumab for the treatment of Crohn's diseaseYvette Leung, Remo PanaccioneBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Anti-adhesion molecule strategies for Crohn diseaseYvette Leung, Remo PanaccioneCurrent Opinion in Gastroenterology|July 16, 2008
Biologic therapy in Crohn's disease: state of the artJennifer Jones, Remo PanaccionePageof 45